NEW YORK (GenomeWeb News) – Magellan Biosciences and Miacom Diagnostics announced on Monday a partnership to bring Miacom's molecular tests to the US and Canada.
The combined offering covered by the agreement includes Magellan's Trek-brand VersaTrek microbial detection system, Miacom's lucesco IVD kits for the identification of bacteria and fungi/yeast from blood cultures, and Magellan's Trek Sensititre susceptibility-testing system.
The lucesco IVD kit will be used on the VersaTrek system to identify pathogens, with microbial susceptibility determined using the Sensititire system.
Under the agreement, Magellan will be the exclusive provider of Bacteremia and Fungimia panels in the US using the Miacom platform, the two companies said. Magellan anticipates marketing a family of Miacom sepsis tests in the US for research-use only, while starting clinical trials in preparation of submission to the US Food and Drug Administration.
Four Miacom tests have been approved for use in Europe.
The tests identify sepsis-related pathogens directly from blood-culture bottles and can achieve results in 30 minutes. Offering Miacom and Magellan's products together "is designed to provide fast, reliable results for laboratories of all sizes, enabling clinicians to make more informed treatment decisions that improve patient care and help in the global fight against drug resistance," Magellan and Miacom said in a joint statement.
Miacom, founded in 2006 and based in Dusseldorf, Germany, has developed a platform for identifying infectious disease-causing bacteria based on proprietary beacon-based fluorescence in situ hybridization technology. In its technology, oligonucleotides are coupled to a fluorophore. The oligonucleotides have a sequence "that is complementary to a target sequence of the ribosomal RNA of an organism and can bind to them," according to the company's website, making synthetic amplification methods, such as PCR, "superfluous."
Based in Chelmsford, Mass., Magellan manufactures products for diagnostic tests, including point-of-care systems to screen for lead poisoning, and automated ELISA processing systems.
Financial and other terms of the deal were not disclosed.